Transplantation of peripheral blood stem cells mobilized by intensified consolidation and granulocyte colony-stimulating factor in acute leukemia

Hong Min Yoo Hong Min, Tae Lee Seung Tae Lee, Seok Kim Jin Seok Kim, Ho Jang Joon Ho Jang, Chan Suh Hyung Chan Suh, Ok Kim Hyun Ok Kim, Sook Hahn Jee Sook Hahn, Woong Ko Yun Woong Ko

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The purpose of this study was to evaluate the feasibility and efficacy of autologous transplantation of peripheral blood stem cells (PBSC) mobilized with high-dose consolidation chemotherapy and granulocyte colony-stimulating factor in patients with acute myelogenous leukemia (AML). Twenty patients received myeloablative chemotherapy or chemo-radiotherapy including total body irradiation followed by the infusion of PBSC. PBSC were collected by large-volume leukaphereses. The mean number of mononuclear cells and CD34-positive cells infused were 7.2 x 108/kg (range, 2.2- 16.6), and 6.6 x 106/kg (range, 2.1-27.7), respectively. Engraftment failure was not seen in the enrolled patients. The median time to neutrophil (≥ 500/μ L) and platelet recovery (≥ 50,000/μ L) from the transplant was 12 days (range, 8-20) and 28 days (range, 10-600), respectively. The 2-year probability of disease-free survival (DFS) and relapse were 43% and 57% for patients with AML transplanted in first complete remission (CR.). The outcome of the patients transplanted in the advanced status was significantly worse than the patients transplanted in CR1 (P=0.04). Most relapses occurred within 1 year after transplantation. Fatal hepatic veno-occlusive disease was observed in one case. Other transplantation-related toxicities were mild. Our results demonstrated that autologous transplantation of high-dose consolidation chemotherapy-mobilized peripheral blood progenitor cells is feasible in the patients with AML in CR1. To further reduce the risk of leukemia relapse, much effort should be contributed to the field of ex vivo purging and post-transplant immunotherapy.

Original languageEnglish
Pages (from-to)65-73
Number of pages9
JournalYonsei medical journal
Volume42
Issue number1
Publication statusPublished - 2001 Apr 18

Fingerprint

Peripheral Blood Stem Cell Transplantation
Granulocyte Colony-Stimulating Factor
Leukemia
Consolidation Chemotherapy
Acute Myeloid Leukemia
Autologous Transplantation
Recurrence
Hepatic Veno-Occlusive Disease
Transplantation
Leukapheresis
Transplants
Whole-Body Irradiation
Immunotherapy
Disease-Free Survival
Blood Cells
Neutrophils
Radiotherapy
Stem Cells
Blood Platelets
Cell Count

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Yoo Hong Min, H. M., Seung Tae Lee, T. L., Jin Seok Kim, S. K., Joon Ho Jang, H. J., Hyung Chan Suh, C. S., Hyun Ok Kim, O. K., ... Yun Woong Ko, W. K. (2001). Transplantation of peripheral blood stem cells mobilized by intensified consolidation and granulocyte colony-stimulating factor in acute leukemia. Yonsei medical journal, 42(1), 65-73.
Yoo Hong Min, Hong Min ; Seung Tae Lee, Tae Lee ; Jin Seok Kim, Seok Kim ; Joon Ho Jang, Ho Jang ; Hyung Chan Suh, Chan Suh ; Hyun Ok Kim, Ok Kim ; Jee Sook Hahn, Sook Hahn ; Yun Woong Ko, Woong Ko. / Transplantation of peripheral blood stem cells mobilized by intensified consolidation and granulocyte colony-stimulating factor in acute leukemia. In: Yonsei medical journal. 2001 ; Vol. 42, No. 1. pp. 65-73.
@article{1df747456c724ec58d6ad59553822823,
title = "Transplantation of peripheral blood stem cells mobilized by intensified consolidation and granulocyte colony-stimulating factor in acute leukemia",
abstract = "The purpose of this study was to evaluate the feasibility and efficacy of autologous transplantation of peripheral blood stem cells (PBSC) mobilized with high-dose consolidation chemotherapy and granulocyte colony-stimulating factor in patients with acute myelogenous leukemia (AML). Twenty patients received myeloablative chemotherapy or chemo-radiotherapy including total body irradiation followed by the infusion of PBSC. PBSC were collected by large-volume leukaphereses. The mean number of mononuclear cells and CD34-positive cells infused were 7.2 x 108/kg (range, 2.2- 16.6), and 6.6 x 106/kg (range, 2.1-27.7), respectively. Engraftment failure was not seen in the enrolled patients. The median time to neutrophil (≥ 500/μ L) and platelet recovery (≥ 50,000/μ L) from the transplant was 12 days (range, 8-20) and 28 days (range, 10-600), respectively. The 2-year probability of disease-free survival (DFS) and relapse were 43{\%} and 57{\%} for patients with AML transplanted in first complete remission (CR.). The outcome of the patients transplanted in the advanced status was significantly worse than the patients transplanted in CR1 (P=0.04). Most relapses occurred within 1 year after transplantation. Fatal hepatic veno-occlusive disease was observed in one case. Other transplantation-related toxicities were mild. Our results demonstrated that autologous transplantation of high-dose consolidation chemotherapy-mobilized peripheral blood progenitor cells is feasible in the patients with AML in CR1. To further reduce the risk of leukemia relapse, much effort should be contributed to the field of ex vivo purging and post-transplant immunotherapy.",
author = "{Yoo Hong Min}, {Hong Min} and {Seung Tae Lee}, {Tae Lee} and {Jin Seok Kim}, {Seok Kim} and {Joon Ho Jang}, {Ho Jang} and {Hyung Chan Suh}, {Chan Suh} and {Hyun Ok Kim}, {Ok Kim} and {Jee Sook Hahn}, {Sook Hahn} and {Yun Woong Ko}, {Woong Ko}",
year = "2001",
month = "4",
day = "18",
language = "English",
volume = "42",
pages = "65--73",
journal = "Yonsei Medical Journal",
issn = "0513-5796",
publisher = "Yonsei University College of Medicine",
number = "1",

}

Yoo Hong Min, HM, Seung Tae Lee, TL, Jin Seok Kim, SK, Joon Ho Jang, HJ, Hyung Chan Suh, CS, Hyun Ok Kim, OK, Jee Sook Hahn, SH & Yun Woong Ko, WK 2001, 'Transplantation of peripheral blood stem cells mobilized by intensified consolidation and granulocyte colony-stimulating factor in acute leukemia', Yonsei medical journal, vol. 42, no. 1, pp. 65-73.

Transplantation of peripheral blood stem cells mobilized by intensified consolidation and granulocyte colony-stimulating factor in acute leukemia. / Yoo Hong Min, Hong Min; Seung Tae Lee, Tae Lee; Jin Seok Kim, Seok Kim; Joon Ho Jang, Ho Jang; Hyung Chan Suh, Chan Suh; Hyun Ok Kim, Ok Kim; Jee Sook Hahn, Sook Hahn; Yun Woong Ko, Woong Ko.

In: Yonsei medical journal, Vol. 42, No. 1, 18.04.2001, p. 65-73.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Transplantation of peripheral blood stem cells mobilized by intensified consolidation and granulocyte colony-stimulating factor in acute leukemia

AU - Yoo Hong Min, Hong Min

AU - Seung Tae Lee, Tae Lee

AU - Jin Seok Kim, Seok Kim

AU - Joon Ho Jang, Ho Jang

AU - Hyung Chan Suh, Chan Suh

AU - Hyun Ok Kim, Ok Kim

AU - Jee Sook Hahn, Sook Hahn

AU - Yun Woong Ko, Woong Ko

PY - 2001/4/18

Y1 - 2001/4/18

N2 - The purpose of this study was to evaluate the feasibility and efficacy of autologous transplantation of peripheral blood stem cells (PBSC) mobilized with high-dose consolidation chemotherapy and granulocyte colony-stimulating factor in patients with acute myelogenous leukemia (AML). Twenty patients received myeloablative chemotherapy or chemo-radiotherapy including total body irradiation followed by the infusion of PBSC. PBSC were collected by large-volume leukaphereses. The mean number of mononuclear cells and CD34-positive cells infused were 7.2 x 108/kg (range, 2.2- 16.6), and 6.6 x 106/kg (range, 2.1-27.7), respectively. Engraftment failure was not seen in the enrolled patients. The median time to neutrophil (≥ 500/μ L) and platelet recovery (≥ 50,000/μ L) from the transplant was 12 days (range, 8-20) and 28 days (range, 10-600), respectively. The 2-year probability of disease-free survival (DFS) and relapse were 43% and 57% for patients with AML transplanted in first complete remission (CR.). The outcome of the patients transplanted in the advanced status was significantly worse than the patients transplanted in CR1 (P=0.04). Most relapses occurred within 1 year after transplantation. Fatal hepatic veno-occlusive disease was observed in one case. Other transplantation-related toxicities were mild. Our results demonstrated that autologous transplantation of high-dose consolidation chemotherapy-mobilized peripheral blood progenitor cells is feasible in the patients with AML in CR1. To further reduce the risk of leukemia relapse, much effort should be contributed to the field of ex vivo purging and post-transplant immunotherapy.

AB - The purpose of this study was to evaluate the feasibility and efficacy of autologous transplantation of peripheral blood stem cells (PBSC) mobilized with high-dose consolidation chemotherapy and granulocyte colony-stimulating factor in patients with acute myelogenous leukemia (AML). Twenty patients received myeloablative chemotherapy or chemo-radiotherapy including total body irradiation followed by the infusion of PBSC. PBSC were collected by large-volume leukaphereses. The mean number of mononuclear cells and CD34-positive cells infused were 7.2 x 108/kg (range, 2.2- 16.6), and 6.6 x 106/kg (range, 2.1-27.7), respectively. Engraftment failure was not seen in the enrolled patients. The median time to neutrophil (≥ 500/μ L) and platelet recovery (≥ 50,000/μ L) from the transplant was 12 days (range, 8-20) and 28 days (range, 10-600), respectively. The 2-year probability of disease-free survival (DFS) and relapse were 43% and 57% for patients with AML transplanted in first complete remission (CR.). The outcome of the patients transplanted in the advanced status was significantly worse than the patients transplanted in CR1 (P=0.04). Most relapses occurred within 1 year after transplantation. Fatal hepatic veno-occlusive disease was observed in one case. Other transplantation-related toxicities were mild. Our results demonstrated that autologous transplantation of high-dose consolidation chemotherapy-mobilized peripheral blood progenitor cells is feasible in the patients with AML in CR1. To further reduce the risk of leukemia relapse, much effort should be contributed to the field of ex vivo purging and post-transplant immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0035066501&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035066501&partnerID=8YFLogxK

M3 - Article

C2 - 11293503

AN - SCOPUS:0035066501

VL - 42

SP - 65

EP - 73

JO - Yonsei Medical Journal

JF - Yonsei Medical Journal

SN - 0513-5796

IS - 1

ER -